Eli Lilly beat earnings and raised its forecast as weight loss drug sales surged

Eli Lilly reported higher-than-expected earnings as revenue from its weight loss drugs Mounjaro and Zepbound surged, with Mounjaro revenue rising 91% to $9.9 billion and Zepbound generating $4.9 billion.